Skip to main content

NIDA Seeks Recommendations on SNPs to Develop 'Neuroarray' Platform

NEW YORK (GenomeWeb News) - The National Institute of Drug Abuse is seeking nominations for SNPs to include in a custom microarray platform it is designing to study the genetics and pharmacogenetics of drug abuse, addiction, and related mental disorders.
 
In a request for information released on Friday, NIDA said that it plans to develop the so-called Neuroarray “pending availability of funds,” and that it is looking for community input on “custom SNPs that provide in-depth coverage of genes with prior knowledge of association with drug addiction and related disorders.”
 
NIDA said it intends to make the array available competitively “through standard NIH mechanisms” to help researchers study genetic vulnerability to addiction and related disorders, and to develop genetic patient profiles for targeted pharmacotherapies.
 
The deadline for responses is March 30. Nominations for SNPs can be submitted here.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.